![Shingo Nakamura](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shingo Nakamura
Direttore/Membro del Consiglio presso REGiMMUNE Corp.
Posizioni attive di Shingo Nakamura
Società | Posizione | Inizio | Fine |
---|---|---|---|
REGiMMUNE Corp.
![]() REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Shingo Nakamura
Precedenti posizioni note di Shingo Nakamura
Società | Posizione | Inizio | Fine |
---|---|---|---|
PRISM BioLab Co., Ltd.
![]() PRISM BioLab Co., Ltd. BiotechnologyHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan. | Direttore/Membro del Consiglio | - | - |
Formazione di Shingo Nakamura
MIT Sloan School of Management | Masters Business Admin |
Stanford University | Graduate Degree |
Waseda University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Giappone | 4 |
Stati Uniti | 3 |
Posizioni
Director/Board Member | 2 |
Masters Business Admin | 1 |
Graduate Degree | 1 |
Settori
Consumer Services | 4 |
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
![]() | Health Technology |
Aziende private | 1 |
---|---|
REGiMMUNE Corp.
![]() REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
- Borsa valori
- Insiders
- Shingo Nakamura
- Esperienza